IBRX

SEC source: 0001200637-26-000004 · wk-form4_1771981498.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 117,548

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001830328-26-000005 · wk-form4_1771981491.xml · derivative · entry 3

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,439

Underlying: Common Stock · 152,439 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001830328-26-000005 · wk-form4_1771981491.xml · nonDerivative · entry 2

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 560,344

F2 · price: On February 22, 2026, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 20, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001830328-26-000005 · wk-form4_1771981491.xml · nonDerivative · entry 1

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 637,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001647994-26-000004 · wk-form4_1771981423.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,081,604

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

SEC source: 0001848899-26-000003 · wk-form4_1770947437.xml · derivative · entry 3

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,474

Underlying: Common Stock · 82,236 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

SEC source: 0001848899-26-000003 · wk-form4_1770947437.xml · nonDerivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 280,175

F2 · price: On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001848899-26-000003 · wk-form4_1770947437.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 322,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001189020-26-000003 · wk-form4_1770949759.xml · derivative · entry 11

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 548,246

Underlying: Common Stock · 274,122 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F11 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

F11 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

SEC source: 0001189020-26-000003 · wk-form4_1770949759.xml · nonDerivative · entry 2

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,701,752

F2 · price: On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001189020-26-000003 · wk-form4_1770949759.xml · nonDerivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,820,312

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001830328-26-000003 · wk-form4_1770947424.xml · derivative · entry 3

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 548,246

Underlying: Common Stock · 274,122 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

SEC source: 0001830328-26-000003 · wk-form4_1770947424.xml · nonDerivative · entry 2

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 485,465

F2 · price: On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001830328-26-000003 · wk-form4_1770947424.xml · nonDerivative · entry 1

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 625,513

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001200637-26-000002 · wk-form4_1770947431.xml · derivative · entry 3

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,965

Underlying: Common Stock · 5,482 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 10, 2025.

SEC source: 0001200637-26-000002 · wk-form4_1770947431.xml · nonDerivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,483

F2 · price: On February 10, 2026, the reporting person's RSUs vested. The closing price of the Issuer's common stock on February 9, 2026 was the settlement price used to calculate the shares withheld.

SEC source: 0001200637-26-000002 · wk-form4_1770947431.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,740

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001647994-26-000002 · wk-form4_1769045681.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,091,604

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

F2 · price: Represents the weighted average share price of an aggregate total of 75,000 shares sold in the price range of $7.87 to $7.8950 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001647994-26-000002 · wk-form4_1769045681.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,166,604

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2024.

SEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · derivative · entry 6

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 92,937

Underlying: Common Stock · 25,000 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.

SEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 4

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

F2 · price: Represents the weighted average share price of an aggregate total of 25,000 shares sold in the price range of $7.50 to $7.52 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 3

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 25,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · derivative · entry 5

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,937

Underlying: Common Stock · 50,000 shares

Expires 2032-06-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: One hundred percent (100%) of the shares subject to the award vested on June 12, 2023, the date immediately preceding the 2023 annual meeting of stockholders.

SEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 2

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 12, 2025.

SEC source: 0001849739-26-000002 · wk-form4_1769045624.xml · nonDerivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001848899-26-000001 · wk-form4_1767654699.xml · derivative · entry 3

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,602

Underlying: Common Stock · 30,397 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F3 · derivative.exercise_date: 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

F3 · derivative.expiration_date: 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

SEC source: 0001848899-26-000001 · wk-form4_1767654699.xml · nonDerivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 240,582

F2 · price: On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001848899-26-000001 · wk-form4_1767654699.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 256,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

SEC source: 0001830328-26-000001 · wk-form4_1767654629.xml · derivative · entry 3

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,731

Underlying: Common Stock · 34,483 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

F3 · derivative.exercise_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

F3 · derivative.expiration_date: Five percent (5%) of the 172,420 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.

SEC source: 0001830328-26-000001 · wk-form4_1767654629.xml · nonDerivative · entry 2

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,391

F2 · price: On December 31, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 30, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001830328-26-000001 · wk-form4_1767654629.xml · nonDerivative · entry 1

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,901

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.

SEC source: 0001364846-25-000007 · wk-form4_1765925747.xml · derivative · entry 1

Wendel Bruce · CIK 0001364846 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,020

Underlying: Common Stock · 146,020 shares

Expires 2035-12-12

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2025 Equity Incentive Plan) through each applicable vesting date, 48,673 of the shares subject to the award will vest on December 12, 2026, 48,673 of the shares subject to the award will vest on December 12, 2027 and 48,674 of the shares subject to the award will vest on December 12, 2028, such that the award will be fully vested on December 12, 2028; provided that, notwithstanding the foregoing, any unvested shares subject to the award will fully vest immediately prior to a Change in Control (as defined in the 2025 Equity Incentive Plan), subject to the reporting person continuing to be a Service Provider through the date of such Change in Control.

SEC source: 0001326110-25-000094 · wk-form4_1750458891.xml · derivative · entry 1

Selecky Christobel · CIK 0001849739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,786

Underlying: Common Stock · 162,786 shares

Expires 2035-06-18

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

SEC source: 0001326110-25-000093 · wk-form4_1750458881.xml · derivative · entry 1

Cohen Cheryl · CIK 0001529371 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,786

Underlying: Common Stock · 162,786 shares

Expires 2035-06-18

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

SEC source: 0001326110-25-000092 · wk-form4_1750458872.xml · derivative · entry 1

BLASZYK MICHAEL D · CIK 0001371407 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,786

Underlying: Common Stock · 162,786 shares

Expires 2035-06-18

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

SEC source: 0001326110-25-000091 · wk-form4_1750458862.xml · derivative · entry 1

MAXWELL LINDA · CIK 0001822674 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,786

Underlying: Common Stock · 162,786 shares

Expires 2035-06-18

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

SEC source: 0001326110-25-000090 · wk-form4_1750458853.xml · derivative · entry 1

Clark Wesley · CIK 0001349193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,786

Underlying: Common Stock · 162,786 shares

Expires 2035-06-18

F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 18, 2026 or the date immediately preceding the Issuer's next annual meeting of stockholders.

SEC source: 0001326110-25-000020 · wk-form4_1740535859.xml · derivative · entry 3

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,488

Underlying: Common Stock · 15,243 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001326110-25-000020 · wk-form4_1740535859.xml · nonDerivative · entry 2

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,243,571

F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-25-000020 · wk-form4_1740535859.xml · nonDerivative · entry 1

Simon Barry J. · CIK 0001647994 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,249,024

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001326110-25-000024 · wk-form4_1740535899.xml · derivative · entry 3

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,130

Underlying: Common Stock · 4,065 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001326110-25-000024 · wk-form4_1740535899.xml · nonDerivative · entry 2

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,258

F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-25-000024 · wk-form4_1740535899.xml · nonDerivative · entry 1

LAUER REGAN J · CIK 0001200637 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,927

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001326110-25-000023 · wk-form4_1740535889.xml · derivative · entry 11

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,658

Underlying: Common Stock · 114,329 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F11 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F11 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001326110-25-000023 · wk-form4_1740535889.xml · nonDerivative · entry 2

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,546,190

F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-25-000023 · wk-form4_1740535889.xml · nonDerivative · entry 1

SOON-SHIONG PATRICK · CIK 0001189020 · Director · See remarks · 10% owner

CALIFORNIA CAPITAL EQUITY, LLC · CIK 0001517764 · 10% owner

MP 13 Ventures, LLC · CIK 0001629186 · 10% owner

Cambridge Equities, LP · CIK 0001629222 · 10% owner

Nant Capital, LLC · CIK 0001675758 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,588,261

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001326110-25-000022 · wk-form4_1740535880.xml · derivative · entry 3

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,301

Underlying: Common Stock · 40,650 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

SEC source: 0001326110-25-000022 · wk-form4_1740535880.xml · nonDerivative · entry 2

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,620

F2 · price: On February 22, 2025, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on February 21, 2025 was the settlement price used to calculate the shares withheld.

SEC source: 0001326110-25-000022 · wk-form4_1740535880.xml · nonDerivative · entry 1

Sachs David C. · CIK 0001848899 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241,480

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

SEC source: 0001326110-25-000021 · wk-form4_1740535870.xml · derivative · entry 3

Adcock Richard · CIK 0001830328 · Director · CEO & President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 304,878

Underlying: Common Stock · 152,439 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. (the "Issuer") common stock.

F3 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.

F3 · derivative.expiration_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 33.33% of the shares subject to the RSU award shall vest in equal annual installments on each of the first and second anniversaries of the vesting commencement date and 33.34% of the shares subject to the RSU award shall vest on the third anniversary of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this RSU award is February 22, 2024.